{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:32:00Z","timestamp":1793518320541,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To summarize the current knowledge of the clinical impact of <jats:italic>Stenotrophomonas maltophilia<\/jats:italic> (<jats:italic>SM<\/jats:italic>) in cystic fibrosis (CF) patients. A systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline recommendations, was performed through searches in PubMed and EMBASE databases, and CF National and International Registries websites from 2000 to 2022. Overall, 184 articles were initially retrieved, out of which 15 were selected and included in the review. Data form 6 Registries and 9 pertinent articles from the references of the studies selected were also considered, resulting in 30 studies in total. The prevalence of <jats:italic>SM<\/jats:italic> in patients with CF is increasing in Europe while it is declining in North America. The role of chronic colonization of <jats:italic>SM<\/jats:italic> on lung function and clinical status in CF patients is still under debate. The most recent studies suggested a pathogenic role of <jats:italic>SM<\/jats:italic> chronic infections in CF patients with an acceleration in lung function decline, an increase in hospitalization rates and an association with co-infection. Reflecting the uncertainty about the role of <jats:italic>SM<\/jats:italic> in CF, little is available about antibiotic therapeutic strategies for both acute exacerbations and chronic infections. Antimicrobial therapy should be performed in the acute exacerbations, while it may be reasonable to attempt eradication when the first colonization is identified. Nevertheless, it is not established which antibiotic regimen should be preferred, and overtreatment could contribute to the selection of antimicrobial-resistant strains. Further studies are warranted in this regard.<\/jats:p>","DOI":"10.1007\/s10096-023-04648-z","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T10:02:32Z","timestamp":1695204152000},"page":"1285-1296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Stenotrophomonas maltophilia in people with Cystic Fibrosis: a systematic review of prevalence, risk factors and management"],"prefix":"10.1007","volume":"42","author":[{"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tomaselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Dalpiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"5","key":"4648_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/apa.15155","volume":"109","author":"K De Boeck","year":"2020","unstructured":"De Boeck K (2020) Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr Int J Paediatr 109(5):893\u2013899. https:\/\/doi.org\/10.1111\/apa.15155","journal-title":"Acta Paediatr Int J Paediatr"},{"issue":"10059","key":"4648_CR2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS (2016) Cystic fibrosis. Lancet 388(10059):2519\u20132531. https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6","journal-title":"Lancet"},{"key":"4648_CR3","doi-asserted-by":"publisher","unstructured":"Scotet V, L\u2019hostis C, F\u00e9rec C (2020) The changing epidemiology of cystic fibrosis: Incidence, survival and impact of the CFTRGene discovery. Genes (Basel) 11(6). https:\/\/doi.org\/10.3390\/genes11060589","DOI":"10.3390\/genes11060589"},{"issue":"4","key":"4648_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","volume":"14","author":"AM Cantin","year":"2015","unstructured":"Cantin AM, Hartl D, Konstan MW, Chmiel JF (2015) In flammation in cystic fi brosis lung disease\u00a0: Pathogenesis and therapy. J Cyst Fibros 14(4):419\u2013430","journal-title":"J Cyst Fibros"},{"issue":"3","key":"4648_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1055\/s-2007-981652","volume":"28","author":"JC Davies","year":"2007","unstructured":"Davies JC, Rubin BK (2007) Emerging and unusual gram-negative infections in cystic fibrosis. Semin Respir Crit Care Med 28(3):312\u2013321. https:\/\/doi.org\/10.1055\/s-2007-981652","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"4648_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00019-18","volume":"31","author":"MD Parkins","year":"2018","unstructured":"Parkins MD, Somayaji R, Waters VJ (2018) Epidemiology, biology, and impact of clonal pseudomonas aeruginosa infections in cystic fibrosis. Clin Microbiol Rev 31(4):1\u201338. https:\/\/doi.org\/10.1128\/CMR.00019-18","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"4648_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1164\/rccm.201009-1533ED","volume":"183","author":"A Colin","year":"2011","unstructured":"Colin A, Rabin H (2011) Stenotrophomonas maltophilia in cystic fibrosis: guilty or innocent? Am J Respir Crit Care Med 183(5):564\u2013566. https:\/\/doi.org\/10.1164\/rccm.201009-1533ED","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4648_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14787210.2020.1730178","volume":"18","author":"T Gil-Gil","year":"2020","unstructured":"Gil-Gil T, Mart\u00ednez JL, Blanco P (2020) Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge. Expert Rev Anti Infect Ther 18(4):335\u2013347. https:\/\/doi.org\/10.1080\/14787210.2020.1730178","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"9","key":"4648_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JCM.01094-21","volume":"59","author":"DD Rhoads","year":"2021","unstructured":"Rhoads DD (2021) Stenotrophomonas maltophilia susceptibility testing challenges and strategies. J Clin Microbiol 59(9):1\u20134. https:\/\/doi.org\/10.1128\/JCM.01094-21","journal-title":"J Clin Microbiol"},{"key":"4648_CR10","doi-asserted-by":"publisher","unstructured":"Armin R, Jahnke N, Waters V (2020) Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev 18(3). https:\/\/doi.org\/10.1002\/14651858.CD009249.pub5.www.cochranelibrary.com","DOI":"10.1002\/14651858.CD009249.pub5.www.cochranelibrary.com"},{"issue":"4","key":"4648_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.21860\/medflum2021_264903","volume":"57","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The prisma 2020 statement: An updated guideline for reporting systematic reviews. Med Flum 57(4):444\u2013465. https:\/\/doi.org\/10.21860\/medflum2021_264903","journal-title":"Med Flum"},{"issue":"6","key":"4648_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jcf.2013.05.009","volume":"12","author":"S Stanojevic","year":"2013","unstructured":"Stanojevic S et al (2013) Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros 12(6):575\u2013583. https:\/\/doi.org\/10.1016\/j.jcf.2013.05.009","journal-title":"J Cyst Fibros"},{"issue":"6","key":"4648_CR13","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1378\/chest.121.6.1754","volume":"121","author":"GR Graff","year":"2002","unstructured":"Graff GR, Burns JL (2002) Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 121(6):1754\u20131760. https:\/\/doi.org\/10.1378\/chest.121.6.1754","journal-title":"Chest"},{"issue":"1","key":"4648_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/1099-0496(200007)30:1<10::AID-PPUL3>3.0.CO;2-Q","volume":"30","author":"I Talmaciu","year":"2000","unstructured":"Talmaciu I, Varlotta L, Mortensen J, Schidlow DV (2000) Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 30(1):10\u201315. https:\/\/doi.org\/10.1002\/1099-0496(200007)30:1<10::AID-PPUL3>3.0.CO;2-Q","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"4648_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/BF01690098","volume":"15","author":"M Denton","year":"1996","unstructured":"Denton M, Todd NJ, Littlewood JM (1996) Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 15(5):402\u2013405. https:\/\/doi.org\/10.1007\/BF01690098","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"4648_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1183\/09031936.03.00007203","volume":"23","author":"V Marchac","year":"2004","unstructured":"Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A (2004) Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J 23(1):98\u2013102. https:\/\/doi.org\/10.1183\/09031936.03.00007203","journal-title":"Eur Respir J"},{"issue":"O1","key":"4648_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/13693786.2010.503665","volume":"48","author":"A Paugam","year":"2010","unstructured":"Paugam A et al (2010) Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 48(O1):32\u201336. https:\/\/doi.org\/10.3109\/13693786.2010.503665","journal-title":"Med Mycol"},{"issue":"5","key":"4648_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jcf.2011.03.006","volume":"10","author":"CS Dalb\u00f8ge","year":"2011","unstructured":"Dalb\u00f8ge CS, Hansen CR, Pressler T, H\u00f8iby N, Johansen HK (2011) Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros 10(5):318\u2013325. https:\/\/doi.org\/10.1016\/j.jcf.2011.03.006","journal-title":"J Cyst Fibros"},{"issue":"5","key":"4648_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jcf.2012.12.006","volume":"12","author":"V Waters","year":"2013","unstructured":"Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F (2013) Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 12(5):482\u2013486. https:\/\/doi.org\/10.1016\/j.jcf.2012.12.006","journal-title":"J Cyst Fibros"},{"issue":"4","key":"4648_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jpeds.2013.11.064","volume":"164","author":"G Com","year":"2014","unstructured":"Com G, Carroll JL, Castro MM, Tang X, Jambhekar S, Berlinski A (2014) Predictors and outcome of low initial forced expiratory volume in 1 second measurement in children with cystic fibrosis. J Pediatr 164(4):832\u2013838. https:\/\/doi.org\/10.1016\/j.jpeds.2013.11.064","journal-title":"J Pediatr"},{"issue":"8","key":"4648_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ppul.23217.Risk","volume":"50","author":"J Cogen","year":"2015","unstructured":"Cogen J et al (2015) Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 50(8):763\u2013770. https:\/\/doi.org\/10.1002\/ppul.23217.Risk","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"4648_CR22","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/ppul.23781","volume":"52","author":"EE Barsky","year":"2017","unstructured":"Barsky EE, Williams KA, Priebe GP, Sawicki GS (2017) Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. Pediatr Pulmonol 52(10):1276\u20131282. https:\/\/doi.org\/10.1002\/ppul.23781","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"4648_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ppul.25741","volume":"57","author":"TS Poore","year":"2022","unstructured":"Poore TS et al (2022) Clinical characteristics of people with cystic fibrosis and frequent fungal infection. Pediatr Pulmonol 57(1):152\u2013161. https:\/\/doi.org\/10.1002\/ppul.25741","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"4648_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/ppul.23943","volume":"53","author":"L Berdah","year":"2018","unstructured":"Berdah L, Taytard J, Leyronnas S, Clement A, Boelle PY, Corvol H (2018) Stenotrophomonas maltophilia: A marker of lung disease severity. Pediatr Pulmonol 53(4):426\u2013430. https:\/\/doi.org\/10.1002\/ppul.23943","journal-title":"Pediatr Pulmonol"},{"key":"4648_CR25","doi-asserted-by":"publisher","unstructured":"Vidigal, P. G., Dittmer, S., Steinmann, E., Buer, J., Rath, P. M., & Steinmann, J. (2014). Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance. International journal of medical microbiology : IJMM, 304(5-6), 613\u2013619. https:\/\/doi.org\/10.1016\/j.ijmm.2014.04.002","DOI":"10.1016\/j.ijmm.2014.04.002"},{"key":"4648_CR26","doi-asserted-by":"publisher","unstructured":"Pompilio\u00a0A et al\u00a0(2016) Stenotrophomonas maltophilia phenotypic and genotypic diversity during a 10-year colonization in the lungs of a cystic fibrosis patient. Front Microbiol vol. 7, no. SEP.\u00a0https:\/\/doi.org\/10.3389\/fmicb.2016.01551","DOI":"10.3389\/fmicb.2016.01551"},{"key":"4648_CR27","doi-asserted-by":"publisher","unstructured":"Esposito\u00a0A et al\u00a0(2017) Evolution of stenotrophomonas maltophilia in cystic fibrosis lung over chronic infection: A genomic and phenotypic population study. Front Microbiol vol. 8, no. AUG.\u00a0https:\/\/doi.org\/10.3389\/fmicb.2017.01590","DOI":"10.3389\/fmicb.2017.01590"},{"key":"4648_CR28","doi-asserted-by":"publisher","unstructured":"Alcaraz E, Centr\u00f3n D, Camicia G, Quiroga MP, Di Conza J and Passerini de Rossi B (2021) Stenotrophomonas maltophilia phenotypic and genotypic features through 4-year cystic fibrosis lung colonization. J Med Microbiol vol. 70, no. 1, Jan.\u00a0https:\/\/doi.org\/10.1099\/jmm.0.001281","DOI":"10.1099\/jmm.0.001281"},{"issue":"1","key":"4648_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1128\/AAC.00954-06","volume":"48","author":"P San Gabriel","year":"2004","unstructured":"San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L (2004) Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 48(1):168\u2013171. https:\/\/doi.org\/10.1128\/AAC.00954-06","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4648_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1128\/AAC.00248-09","volume":"54","author":"P King","year":"2010","unstructured":"King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN (2010) In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 54(1):143\u2013148. https:\/\/doi.org\/10.1128\/AAC.00248-09","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4648_CR31","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","volume":"204","author":"CH Goss","year":"2021","unstructured":"Goss CH et al (2021) A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. Am J Respir Crit Care Med 204(11):1295\u20131305. https:\/\/doi.org\/10.1164\/rccm.202102-0461OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4648_CR32","doi-asserted-by":"publisher","unstructured":"Capaldo C, Beauruelle C, Saliou P, Rault G, Ramel S, H\u00e9ry-Arnaud G (2020) Investigation of Stenotrophomonas maltophilia epidemiology in a French cystic fibrosis center. Respir Med Res 78. https:\/\/doi.org\/10.1016\/j.resmer.2020.100757","DOI":"10.1016\/j.resmer.2020.100757"},{"issue":"1","key":"4648_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-017-2511-9","volume":"17","author":"KJ Psoter","year":"2017","unstructured":"Psoter KJ, De Roos AJ, Wakefield J, Mayer JD, Rosenfeld M (2017) Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. BMC Infect Dis 17(1):1\u20136. https:\/\/doi.org\/10.1186\/s12879-017-2511-9","journal-title":"BMC Infect Dis"},{"issue":"11","key":"4648_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/thx.2003.017707","volume":"59","author":"CH Goss","year":"2004","unstructured":"Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW (2004) Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 59(11):955\u2013959. https:\/\/doi.org\/10.1136\/thx.2003.017707","journal-title":"Thorax"},{"issue":"1","key":"4648_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jcf.2011.07.008","volume":"11","author":"V Waters","year":"2012","unstructured":"Waters V et al (2012) Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 11(1):8\u201313. https:\/\/doi.org\/10.1016\/j.jcf.2011.07.008","journal-title":"J Cyst Fibros"},{"issue":"4","key":"4648_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"4648_CR37","unstructured":"Cystic Fibrosis Foundation Patient Registry (2021) Annual Data Report, 2021. https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf"},{"key":"4648_CR38","unstructured":"European Cystic Fibrosis Society Patient Registry 2021Annual Data Report 2021 (2023). https:\/\/www.ecfs.eu\/sites\/default\/files\/Annual%20Report_2021_09Jun2023.pdf"},{"issue":"4 Suppl 2","key":"4648_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19191\/EP22.4S2.060","volume":"46","author":"G Campagna","year":"2022","unstructured":"Campagna G et al (2022) Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020. Epidemiol Prev 46(4 Suppl 2):1\u201338. https:\/\/doi.org\/10.19191\/EP22.4S2.060","journal-title":"Epidemiol Prev"},{"key":"4648_CR40","unstructured":"French Cystic Fibrosis Registry (2021) Annual Data Report, 2021. https:\/\/www.vaincrelamuco.org\/sites\/default\/files\/french_cf_registry_annual_data_report_2021.pdf"},{"key":"4648_CR41","unstructured":"Australian Cystic Fibrosis Data Registry (2021) Annual Report, 2022. https:\/\/cysticfibrosis.org.au\/wp-content\/uploads\/2023\/05\/2021-ACFDR-Annual-Report.pdf"},{"key":"4648_CR42","unstructured":"The Canadian Cystic Fibrosis Registry (2021) Annual Report, 2023. https:\/\/www.cysticfibrosis.ca\/registry\/2021AnnualDataReport.pdf"},{"key":"4648_CR43","unstructured":"Canadian Cystic Fibrosis Registry (2017) Annual Data Report, 2018. https:\/\/www.cysticfibrosis.ca\/registry\/2017AnnualDataReport.pdf"},{"key":"4648_CR44","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1164\/ajrccm\/141.4_Pt_1.914","volume":"141","author":"C Regelmann","year":"1990","unstructured":"Regelmann C, Elliott WE, Warwick GR, Clawson WJ (1990) Reduction of Sputum Pseudomonas aeruginosa Density by Antibiotics Improves Lung Function in Cystic Fibrosis More than Do Bronchodilators and Chest Physiotherapy Alone. Am Rev Respir Dis 141:914\u2013921","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"4648_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/CMR.00019-11","volume":"25","author":"JS Brooke","year":"2012","unstructured":"Brooke JS (2012) Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. Clin Microbiol Rev 25(1):2\u201341. https:\/\/doi.org\/10.1128\/CMR.00019-11","journal-title":"Clin Microbiol Rev"},{"key":"4648_CR46","doi-asserted-by":"publisher","unstructured":"Chang\u00a0YT, Lin CY, Chen YH and Hsueh PR (2015) Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol vol. 6, no. SEP, pp. 1\u201320.\u00a0https:\/\/doi.org\/10.3389\/fmicb.2015.00893","DOI":"10.3389\/fmicb.2015.00893"},{"issue":"11","key":"4648_CR47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01433-20","volume":"64","author":"HS Sader","year":"2020","unstructured":"Sader HS, Duncan LR, Arends SJR, Carvalhaes CG, Castanheira M (2020) Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide. Antimicrob. Agents Chemother 64(11):6\u201311. https:\/\/doi.org\/10.1128\/AAC.01433-20","journal-title":"Antimicrob. Agents Chemother"},{"key":"4648_CR48","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D and Clancy CJ (2022) Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis vol. 74, no. 12, pp. 2089\u20132114, Jul. https:\/\/doi.org\/10.1093\/cid\/ciab1013","DOI":"10.1093\/cid\/ciab1013"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04648-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T12:03:42Z","timestamp":1697717022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04648-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["4648"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04648-z","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}